

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Osamu HONMOU et al.

Title:

INTERNALLY ADMINISTERED

THERAPEUTIC AGENTS FOR DISEASES

IN CENTRAL AND PERIPHERAL NERVOUS SYSTEM COMPRISING

MESENCHYMAL CELLS AS AN ACTIVE

INGREDIENT (As Amended)

Appl. No.:

10/562,202

International

6/25/2004

Filing Date:

371(c) Date:

4/13/06

Examiner:

Unassigned

Art Unit:

3629

Conf. No.:

4131

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

## RELEVANCE OF EACH DOCUMENT

All of the documents are in English, and were cited by the Examiner in US Application No. 11/377,610, which is a Continuation-In-Part of the present application.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 6, 2007

**FOLEY & LARDNER LLP** Customer Number: 22428

Telephone:

(202) 672-5569

Facsimile:

(202) 672-5399

Stephen B. Maebius Mathew Nulkeen Attorney for Applicant Reg No 44, 250 Registration No. 35,264

WASH\_1890960.1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

19,	Substitute for form 1449/PTO		Complete if Known	
	S INFORMATION DISCLOSURE	Application Number	10/562,202	
N 0 6 2007	STATEMENT BY APPLICANT	Filing Date	6/25/2004	
14 00	6 Data Submitted June 6 2007	First Named Inventor	Osamu HONMOU	
	Date Submitted: June 6, 2007	Art Unit	3629	
- MAR	(use as many sheets as necessary)	Examiner Name	Unassigned	
Sheet	1 of 1	Attorney Docket Number	033873-0108	

U.S. PATENT DOCUMENTS					
Examiner Cite Document Number Publication Date Name of Patente		Name of Patentee or Applicant of	Pages, Columns, Lines, or Applicant of Where Relevant		
Initials*	No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	C1	2003/0161818 A1	08/28/2003	Weiss et al.	
					· · · · · · · · · · · · · · · · · · ·

FOREIGN PATENT DOCUMENTS					
Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3-</sup> Number <sup>4-</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
C2	WO 99/01145	01/14/1999	Osiris Therapeutics, Inc.		
C3	WO 01/005944 A1	01/25/2001	University of Southern California		
	No. <sup>1</sup>	No. <sup>1</sup> Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )  C2 WO 99/01145	Cite No.1 Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) Publication Date MM-DD-YYYY  C2 WO 99/01145 01/14/1999	Cite No.1 Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) Publication Date MM-DD-YYYY Applicant of Cited Documents  C2 WO 99/01145 01/14/1999 Osiris Therapeutics, Inc.  C3 WO 01/005944 A1 01/25/2001 University of Southern	Cite No. 1 Foreign Patent Document Country Code Number Kind Code (if known) Publication Date MM-DD-YYYY Applicant of Cited Documents Passages or Relevant Figures Appear  C2 WO 99/01145 01/14/1999 Osiris Therapeutics, Inc.  C3 WO 01/005944 A1 01/25/2001 University of Southern

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	4 I Item (book madazine journal serial symposium catalog etc.) date pade(s) volume-issue number(s)				
	C4	KENNEA et al., "Perinatal applications of neural stem cells," Best Practice & Research Clinical Obstetrics and Gynaecology, 2004, 18(6), 977-994.			
	C5	TOCCI et al., "Mesenchymal stem cell: use and perspectives," The Hematology Journal, 2003, 4, 92-96.			

Examiner Signature Date Considered		<u> </u>	
		Date	
	Signature		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.